-
1.发明授权Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator 失效用于干扰素的增效剂和含有干扰素及其增效剂的抗病毒活性增强组合物
公开(公告)号：US5730971A
公开(公告)日：1998-03-24
申请号：US361442
申请日：1994-12-20
IPC分类号： A61K31/525 , A61K31/675 , A61K31/70 , A61K35/407 , A61K38/21 , A61P31/12 , A61P43/00
CPC分类号： A61K31/70 , A61K35/407 , A61K38/21
摘要： A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.
摘要翻译： 提供了一种干扰素增强剂和含有干扰素及其增效剂的抗病毒活性增强组合物。 增效剂是黄素腺嘌呤二核苷酸（FAD）和猪肝提取物的混合物。
-
公开(公告)号：US5560925A
公开(公告)日：1996-10-01
申请号：US316848
申请日：1994-10-03
摘要： Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.
摘要翻译： 通过给药含有具有经验式为C 6 H 10 Ge 2 O 7的2-氧基甲基丙酸的八种结构聚合物的药物组合物，（O + E，fra 1/2 + EE）3GeCH 2 CH 2 COOH的最小结构单元和 以下立体结构：其中R代表-CH2CH2COOH，m是137 +/- 84的整数。
-
公开(公告)号：US5260056A
公开(公告)日：1993-11-09
申请号：US640750
申请日：1991-01-14
申请人： Kiichi Sawai , Masayasu Kurono , Takahiko Mitani , Naohisa Ninomiya , Yoshiro Ishiwata , Syoji Yokochi , Kyoichi Asano , Kaneo Yamada , Masashi Taki , Takashi Meguro , Mikio Minamitani , Takao Matumoto , Yuichi Shiokawa
发明人： Kiichi Sawai , Masayasu Kurono , Takahiko Mitani , Naohisa Ninomiya , Yoshiro Ishiwata , Syoji Yokochi , Kyoichi Asano , Kaneo Yamada , Masashi Taki , Takashi Meguro , Mikio Minamitani , Takao Matumoto , Yuichi Shiokawa
摘要： An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.
摘要翻译： 有效地用于治疗AIDS或以各种形式产生AIDS的有机锗化合物由以下有理式表示：其中n为1或2或更大的整数，为白色针状或 针状结晶，在25℃的水中的溶解度为1.570 / 100ml，熔点（分解）为240℃。
-
公开(公告)号：US5621003A
公开(公告)日：1997-04-15
申请号：US515330
申请日：1995-08-15
CPC分类号： A61K31/80
摘要： A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOHand the following empirical formula:C.sub.6 H.sub.10 Ge.sub.2 O.sub.7,a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.
摘要翻译： 一种美拉德反应抑制剂，其包含由以下立体结构（I）表示的3-氧基甲基丙酸的8-结构聚合物作为主要组分：其中R表示-CH 2 CH 2 COOH，m表示重均聚合度 基于丙基丙基酯的重均分子量计算，为137 +/- 84（平均137个，标准偏差为+/- 3西格玛）; 并具有以下最小结构单元：（O + E，fra 1/2 + EE）3GeCH 2 CH 2 COOH和以下经验式：C 6 H 10 Ge 2 O 7，抑制美拉德反应的方法，以及预防和治疗美拉德反应引起的疾病的方法 作为糖尿病及其并发疾病。
-
公开(公告)号：US5356880A
公开(公告)日：1994-10-18
申请号：US889709
申请日：1992-05-28
申请人： Masayasu Kurono , Yoshiro Ishiwata , Syoji Yokochi , Kyoichi Asano , Takahiko Mitani , Takuji Kakigami , Noriyuki Iwata , Kougaku Isogawa , Yutaka Baba , Hiroyuki Ohwaki , Kiichi Sawai , Hiromoto Kimura , Masato Fukushima , Ryoichi Unno , Tamaki Ohtuka
发明人： Masayasu Kurono , Yoshiro Ishiwata , Syoji Yokochi , Kyoichi Asano , Takahiko Mitani , Takuji Kakigami , Noriyuki Iwata , Kougaku Isogawa , Yutaka Baba , Hiroyuki Ohwaki , Kiichi Sawai , Hiromoto Kimura , Masato Fukushima , Ryoichi Unno , Tamaki Ohtuka
IPC分类号： C07C61/35 , C07C62/38 , C07C323/41 , C07D295/185 , C07H15/256 , C07J63/00 , A61K31/58 , C07J43/00
CPC分类号： C07D295/185 , C07C323/41 , C07C61/35 , C07C62/38 , C07H15/256 , C07J63/008 , C07C2103/52
摘要： The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.
摘要翻译： 本发明提供了一种新颖的糖苷，其含有作为糖苷配基的甘草次酸和11-脱氧甘草次酸或其衍生物的4-（取代苯基）哌嗪-1-基衍生物以及用于治疗病毒感染的组合物，其中 含有这些化合物作为主要活性组分。
-
6.发明授权
公开(公告)号：US5279835A
公开(公告)日：1994-01-18
申请号：US906465
申请日：1992-06-30
申请人： Kiichi Sawai , Masayasu Kurono , Takahiko Mitani , Yasuaki Kondo , Makoto Sato , Yoshiro Ishiwata , Syoji Yokochi , Toshiyuki Kouzaki
发明人： Kiichi Sawai , Masayasu Kurono , Takahiko Mitani , Yasuaki Kondo , Makoto Sato , Yoshiro Ishiwata , Syoji Yokochi , Toshiyuki Kouzaki
CPC分类号： A61K31/80 , A61K31/28 , A61K9/2009 , A61K9/2018
摘要： A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.
摘要翻译： 提供了3-氧基甲基丙酸制剂，其活化具有以下通式的3-氧基甲基丙酸的作用：（（O1 / 2）3GeCH2CH2COOH）n，其中n =至少为1的整数，并且在体内容易溶解和分解。 本制剂通过高压压缩成型制备，该组合物包含3-氧基甲基丙酸和两种或更多种在水中的高溶解度的低分子量物质。 低分子物质选自白糖，山梨糖醇，果糖，蔗糖，葡萄糖，乳糖，甘露醇和氯化钠。
-
公开(公告)号：US06809113B2
公开(公告)日：2004-10-26
申请号：US10087208
申请日：2002-02-27
申请人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
发明人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
IPC分类号： A61K3135
CPC分类号： C07D401/12 , C07D215/48 , C07D241/42 , C07D265/36 , C07D319/18 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要： Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.
摘要翻译： 作为MCP-1拮抗剂的化合物起作用，可用于预防或治疗慢性或急性炎性或自身免疫性疾病，特别是与异常淋巴细胞或单核细胞积累相关的疾病如关节炎，哮喘，动脉粥样硬化，糖尿病性肾病，炎性肠病， 克罗恩病，多发性硬化，肾炎，胰腺炎，肺纤维化，牛皮癣，再狭窄和移植排斥反应; 包含这些化合物的药物组合物; 以及这些化合物和组合物在预防或治疗这些疾病中的用途。
-
公开(公告)号：US06998407B2
公开(公告)日：2006-02-14
申请号：US10716652
申请日：2003-11-18
申请人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
发明人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
IPC分类号： A61K31/36 , A61K31/343 , C07D307/79 , C07D317/60
CPC分类号： C07D235/06 , C07D209/08 , C07D249/18 , C07D263/56 , C07D307/79 , C07D317/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要： Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.
摘要翻译： 作为单核细胞趋化蛋白-1（MCP-1）功能拮抗剂的化合物，包含这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及制备这些化合物的方法。 该化合物可用于预防或治疗慢性或急性炎性或自身免疫疾病，特别是与异常淋巴细胞或单核细胞积累相关的疾病，如关节炎，哮喘，动脉粥样硬化，糖尿病性肾病，炎性肠病，克罗恩病，多发性硬化，肾炎， 胰腺炎，肺纤维化，牛皮癣，再狭窄和移植排斥。
-
公开(公告)号：US06992086B2
公开(公告)日：2006-01-31
申请号：US10716363
申请日：2003-11-17
申请人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
发明人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
IPC分类号： A61K31/496 , A61K31/437 , C07D498/04 , C07D471/04 , A61P37/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
-
公开(公告)号：US06677365B2
公开(公告)日：2004-01-13
申请号：US10106881
申请日：2002-03-25
申请人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
发明人： Edgardo Laborde , Louise Robinson , Fanying Meng , Brian T. Peterson , Hugo O. Villar , Steven E. Anuskiewicz , Yoshiro Ishiwata , Shoji Yokochi , Yukiharu Matsumoto , Takuji Kakigami , Hideaki Inagaki , Takahito Jomori , Kouji Matsushima
IPC分类号： A61K3142
CPC分类号： C07D235/06 , C07D209/08 , C07D249/18 , C07D263/56 , C07D307/79 , C07D317/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
摘要： Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.022 秒)
